Search results
Recommendations from the AML molecular MRD expert advisory board - Leukemia
Nature· 2 days agoThe standard-of-care treatment for patients with acute myeloid leukemia (AML) is being challenged by new classes of ...
Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
WROC Rochester· 22 hours agoOral presentation of final five-year results from the registrational Phase 2 trial in R/R mIDH1 AML patients reinforces REZLIDHIA® (olutasidenib) efficacy in heavily pretreated patients, including ...
Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells - Leukemia
Nature· 3 days agoMyelodysplastic syndromes (MDS) are malignant bone marrow disorders characterized by ineffective hematopoiesis leading to refractory cytopenias and an increased risk of progression to
Newswise Expert | Namrata Chandhok, University of Miami Health System, Miller School of Medicine
Newswise· 4 days agoNamrata Chandhok, M.D. is an Assistant Professor of Clinical Medicine (Hematology) at the University of Miami Miller School of Medicine/ Sylvester Comprehensive Cancer Center. Dr. Chandhok specializes ...
NCI-MATCH Precision Medicine Clinical Trial
National Cancer Institute· 1 day agoNCI-MATCH, also known as MATCH, is a precision medicine cancer treatment clinical trial that sought to find out if treating cancer based on specific...
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com
ETF DAILY NEWS· 2 days agoStockNews.com assumed coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a research note released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock ...
MD Anderson Research Highlights for May 21, 2024 | Newswise
Newswise· 4 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These
Innovative Techniques Open New Avenues in Drug Dis | Newswise
Newswise· 2 days agoVolume 29, Issue 2 of SLAS Discovery features two review articles, six original research articles...
ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug...
WRBL Columbus· 18 hours agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its ...
The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035
InvestorPlace· 1 day agoOne of the hottest investment trends to jump on at the moment is machine learning stocks to buy. Along the way, machines will learn from historical data, identify patterns, and make logical ...